NSD1 and synovial sarcoma: To determine whether NSD1 loss-of-function mutations impact stable epigenetic marks such as DNAm at downstream genomic targets, we compared DNAm in peripheral blood from SS patients with known pathogenic NSD1 mutations (NSD1+/−; n=19) to controls (n=53) (Supplementary Data 1 and 2).